Dopamine Uptake Inhibitors
"Dopamine Uptake Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake.
| Descriptor ID |
D018765
|
| MeSH Number(s) |
D27.505.519.562.437.220 D27.505.519.625.150.800 D27.505.519.625.600.220 D27.505.696.577.150.800 D27.505.696.577.600.220
|
| Concept/Terms |
Dopamine Uptake Inhibitors- Dopamine Uptake Inhibitors
- Reuptake Inhibitors, Dopamine
- Inhibitors, Dopamine Uptake
- Uptake Inhibitors, Dopamine
- Inhibitors, Dopamine Reuptake
- Dopamine Reuptake Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Dopamine Uptake Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Dopamine Uptake Inhibitors".
This graph shows the total number of publications written about "Dopamine Uptake Inhibitors" by people in this website by year, and whether "Dopamine Uptake Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 3 | 1 | 4 |
| 2006 | 1 | 0 | 1 |
| 2007 | 4 | 2 | 6 |
| 2008 | 2 | 1 | 3 |
| 2009 | 1 | 1 | 2 |
| 2010 | 2 | 1 | 3 |
| 2011 | 2 | 1 | 3 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dopamine Uptake Inhibitors" by people in Profiles.
-
An autophagy-related protein Becn2 regulates cocaine reward behaviors in the dopaminergic system. Sci Adv. 2021 02; 7(8).
-
Midbrain D3 Receptor Availability Predicts Escalation in Cocaine Self-administration. Biol Psychiatry. 2020 11 15; 88(10):767-776.
-
Monitoring Dopamine Responses to Potassium Ion and Nomifensine by in Vivo Microdialysis with Online Liquid Chromatography at One-Minute Resolution. ACS Chem Neurosci. 2017 02 15; 8(2):329-338.
-
Excessive Sensory Stimulation during Development Alters Neural Plasticity and Vulnerability to Cocaine in Mice. eNeuro. 2016 Jul-Aug; 3(4).
-
Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015 Mar; 72(3):235-46.
-
Commentary on Chen et?al. (2014): another step on the road to clinical utility of pharmacogenetics for smoking cessation? Addiction. 2014 Jan; 109(1):138-9.
-
Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction. 2013 Dec; 108(12):2202-11.
-
Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo. J Neurochem. 2013 Oct; 127(2):187-98.
-
Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008. Psychiatr Serv. 2013 Apr 01; 64(4):339-46.
-
Personality and the acute subjective effects of d-amphetamine in humans. J Psychopharmacol. 2013 Mar; 27(3):256-64.